硝苯地平缓释微丸家犬体内药动学和生物利用度
硝苯地平缓释微丸,,硝苯地平；海藻酸钠；缓释微丸；控释片；药动学；生物利用度,1实验材料,2实验方法,3结果,4讨论
摘 要 目的：研究硝苯地平缓释微丸在家犬体内的药动学及生物利用度。方法：家犬自身交叉对照分别口服单剂量硝苯地平缓释微丸(A)和进口硝苯地平控释片(B)各30 mg, 采用反相高效液相色谱法测定血药浓度,应用3P87药动学程序对血药浓度数据进行拟合。结果：硝苯地平缓释微丸和进口硝苯地平控释片的药动学参数：Tmax分别为3.47和5.41 h；Cmax分别为25.7和20.2 ng·mL-1；AUC0～∞分别为216和168 mg·h·mL-1。以B为参比制剂，单剂量给药时A的相对生物利用度为129%。结论：两种制剂单剂量给药30 mg为生物不等效。关键词 硝苯地平；海藻酸钠；缓释微丸；控释片；药动学；生物利用度
Pharmacokinetics and relative bioavailability of nifedipine
sustained release pellets
MA Ping, ZHU Li, SUN Shuying, XIN Yanru, YANG Jingyan, GAO WenJing
(1.General Hospital of Rocket Forces, Beijing 100088；2.Shengyang University of Pharmaceutical Sciences, Shengyang110015)
Abstract Objective:To study the pharmacokinetics and relative bioavailability of nifedipine sustained release pellets. Methods: The plasma concentration of nifedipine was determined by HPLC. The data was processed with the software 3P87. Results: The parameters of the two formulations for nifedipine: Tmax of the pellets and tablets were 3.47 and 5.41 h；Cmax were 25.7 and 20.2 ng/mL；and AUC0～∞were 216 and 168 mg·h·mL-1 respectively. The bioavailability of nifidipine sustained pellets with reference to nifedipine controlled-release tablets is 129%. Conclusions: The results of single oral administration 30 mg nifidipine demonstrated that two formulations were not bioequivalent. ......
您现在查看是摘要页，全文长 6403 字符。